Clinical Trial Update: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety of TAK-279 and its potential to reduce bowel inflammation in moderately to severely active ulcerative colitis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• TAK-279

Snippet

Sponsor: Takeda | Conditions: Ulcerative Colitis | Phase 2 | Status: RECRUITING